Clinical trials: Mental
Chronic Insomnia
A Study of Ramelteon in Chinese Patients With Chronic Insomnia
The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia. Efficacy will be evaluated on objective and subjective sleep parameters.
- Trial name
- NCT06512363
- Testing
- Ramelteon
- Volunteers
- 280 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Respiratory Insufficiency, Sleep Disordered Breathing
Adjustment of Mask Pressure, for Bilevel Positive Airways Pressure Therapy, by Automated Algorithm
The aim of the study is to test the hypothesis that an automated algorithm for desired mask pressure improves breathing pattern and sleep quality in patients with hypercapnic ventilatory failure.
- Trial name
- NCT01403584
- Testing
- AutoVPAP with addition of AutoEPAP, AutoVPAP with EPAP manually selected
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- ResMed
Posttraumatic Stress Disorder
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
- Trial name
- NCT00353938
- Testing
- 3,4-methylenedioxymethamphetamine (125 mg), 3,4-methyelendioxymethamphetamine (25 mg), Therapy
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Resilient Pharmaceuticals
Attention Deficit Hyperactivity Disorder
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT01439126
- Testing
- clonidine hydrochloride
- Volunteers
- 135 people
- Sponsor
- Concordia Pharmaceuticals Inc., Barbados
Generalized Anxiety Disorder
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.
- Trial name
- NCT00542685
- Testing
- PD 0332334
- Where
- 43 sites in United States
- Volunteers
- 551 people
- Sponsor
- Pfizer
Mild Cognitive Impairment
Computer-Based Therapy for Mild Cognitive Impairment
The purpose of this study is to determine the neuropsychological and neurophysiological impacts of a computer-based training program designed to improve the cognitive performance of patients with mild cognitive impairment (MCI).
- Trial name
- NCT00319943
- Testing
- Computer-based training for Mild Cognitive Impairment (MCI)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Posit Science Corporation
Diabetes Mellitus, Type 2, Insomnia
A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on glucose lipid metabolism and sleep is studied…
- Trial name
- NCT00869128
- Testing
- Circadin
- Volunteers
- 36 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Osteoporosis
The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa
The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
- Trial name
- NCT00320567
- Testing
- norgestimate/ethinyl estradiol
- Volunteers
- 123 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences
Tourette's Syndrome
Ecopipam Treatment of Tourette Syndrome
Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate.
- Trial name
- NCT01244633
- Testing
- Ecopipam
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Psyadon Pharma
Social Anxiety Disorder (SAD)
A Study of ONO-1110 in Patients With Social Anxiety Disorder
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Social Anxiety Disorder
- Trial name
- NCT06805565
- Testing
- ONO-1110
- Where
- 27 sites in Japan
- Volunteers
- 115 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
MCI, Cognitive Ability, General
ViewMind Atlas Cognition
The objective of this study is to demonstrate the clinical validity, analytical validity and safety of ViewMind Atlas as an adjunctive tool to be used by healthcare professionals (HCP) evaluating cognitive impairment in adults…
- Conditions
- MCI, Cognitive Ability, General, Cognitive Decline, Cognition
- Trial name
- VM-Cog (NCT06746844)
- Testing
- ViewMind Atlas™
- Where
- Argentina
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- ViewMind
Major Depressive Disorder
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication.
- Trial name
- NCT01380704
- Testing
- ABT-436
- Volunteers
- 51 people
- Sponsor
- AbbVie
Major Depressive Disorder
Self-guided Treatment for Depression
This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.
- Trial name
- NCT06028984
- Testing
- Intervention app, Control app
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Big Health Inc.
Bradyarrhythmia
Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications OPTI-MIND 2
The purpose of the study is to demonstrate that reduction of unnecessary pacing provided by RYTHMIQ algorithm programed to ON in a pacemaker is associated with better clinical outcomes in bradycardia target population.
- Trial name
- OPTI-MIND 2 (NCT01715558)
- Where
- 39 sites in Belgium, Denmark and 7 more
- Volunteers
- 514 people
- Sponsor
- Boston Scientific Corporation
Restless Legs Syndrome
A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
The primary objective is to assess sustained efficacy in patients who have responded to a 6 month treatment with open-label pramipexole.
- Trial name
- NCT00152958
- Testing
- Pramipexole
- Where
- 12 sites in Germany
- Volunteers
- 224 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Schizophrenia
Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole)
Single dose oral bioequivalence study of Brexpiprazole 4 mg Film Coated Tablets and RXULTI® (Brexpiprazole) 4 mg film-coated tablets in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07266792
- Testing
- Brexpiprazole Film Coated Tablets, RXULTI film coated tablet
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Huntington's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
- Trial name
- NCT02519036
- Testing
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Treatment Resistant Depressive Disorder
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).
- Trial name
- NCT05196971
- Testing
- HS-10345 84mg
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.